BidaskClub upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a strong sell rating to a sell rating in a report issued on Friday morning, BidAskClub reports.

A number of other analysts also recently issued reports on ENTA. Zacks Investment Research downgraded Enanta Pharmaceuticals from a hold rating to a sell rating in a report on Friday, November 22nd. Berenberg Bank set a $130.00 price objective on Enanta Pharmaceuticals and gave the company a buy rating in a report on Wednesday, September 18th. ValuEngine raised Enanta Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Friday, November 1st. JMP Securities cut Enanta Pharmaceuticals from an outperform rating to a market perform rating in a research note on Friday, November 22nd. Finally, JPMorgan Chase & Co. downgraded Enanta Pharmaceuticals from a neutral rating to an underweight rating and lowered their price target for the company from $86.00 to $57.00 in a report on Thursday, September 26th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $96.50.

Shares of ENTA opened at $64.08 on Friday. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 29.00 and a beta of 0.90. The firm’s fifty day simple moving average is $61.83 and its 200-day simple moving average is $73.38. Enanta Pharmaceuticals has a twelve month low of $57.15 and a twelve month high of $106.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Thursday, November 21st. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.12). Enanta Pharmaceuticals had a return on equity of 10.46% and a net margin of 22.60%. The firm had revenue of $51.30 million for the quarter, compared to analyst estimates of $55.95 million. During the same quarter in the previous year, the firm posted $1.30 EPS. The business’s revenue for the quarter was down 23.7% on a year-over-year basis. Equities research analysts expect that Enanta Pharmaceuticals will post -0.77 EPS for the current year.

A number of large investors have recently made changes to their positions in the stock. Point72 Asset Management L.P. purchased a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $34,000. Robeco Institutional Asset Management B.V. purchased a new stake in Enanta Pharmaceuticals in the third quarter valued at approximately $48,000. Bank of Montreal Can grew its position in shares of Enanta Pharmaceuticals by 198.3% during the second quarter. Bank of Montreal Can now owns 2,300 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 1,529 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at $208,000. Finally, GAM Holding AG acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at $215,000. Hedge funds and other institutional investors own 89.60% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Recommended Story: What are catch-up contributions?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with's FREE daily email newsletter.